Repeated exposure to a conserved antigen drives dynamic clonal and epitope succession
Defining the dynamics of T cell memory formation with epitope-level resolution can inform vaccine design. Longitudinal T cell receptor (TCR) sequencing after COVID-19 mRNA vaccination has enabled detailed tracking of T cell responses; however, connecting expanded clonotypes following antigen exposure to their cognate epitopes remains a challenge due to limited curated paired α/βTCR information. To fill this gap, we used TIRTL-seq to identify paired α/βTCRs from CD8+ T cell lineages associated with mRNA immunization in serial samples across 38 healthy donors over multiple rounds of vaccinations. Vaccine-associated paired α/βTCRs, identified based on their longitudinal kinetics, were grouped according to sequence similarity to infer their shared epitope specificities. We assigned epitope specificity to 1,109 clonotypes, recognizing 15 SARS-CoV-2 spike targets, identifying multiple previously undescribed responses, and confirming putative specificities experimentally. This approach uncovered a striking pattern of clonal succession in anti-spike T cell memory lineages resulting from repeated vaccination, characterized by a transition from low-avidity clones recognizing conserved coronavirus epitopes to high-avidity clones targeting epitopes unique to SARS-CoV-2. These results highlight the surprisingly dynamic responses underlying homologous boosting, suggest avenues for improving vaccine strategies, and pave the way for repertoire-based monitoring of antigen-specific T cell immunity. ### Competing Interest Statement P.G.T. is on the Scientific Advisory Board of Immunoscape and Shennon Bio, has received research support and personal fees from Elevate Bio, and consulted for 10X Genomics, Illumina, Pfizer, Cytoagents, Sanofi, Merck, and JNJ. P.G.T., M.V.P., and A.A.M. have patents related to TCR amplification, cloning and/or applications thereof. P.X. is currently a full-time employee of ImmunoGeneTeqs, Inc. T.I. reports research funding from Rohto Pharmaceutical Co., Ltd and Biometrics Sympathies Inc. K.M. reports stock for ImmunoGeneTeqs, Inc. S.U. reports an advisory role for ImmunoGeneTeqs, Inc. and stock for ImmunoGeneTeqs, Inc. The other authors declare no competing interests. National Institutes of Health, https://ror.org/01cwqze88, R01 AI136514, U19 AI181103, P01 AI165077, R35 GM141457 St. Jude Center for Influenza Research and Response (SJCEIRR), 75N93021C0016 Center for Influenza Vaccine Research in High Risk Populations (CIVR-HRP), 75N93019C00052 Cancer Research Institute Irvington Postdoctoral Fellowship, CRI14316 Japan Agency for Medical Research and Development, https://ror.org/004rtk039, JP256f0137011, JP22fk0310509, JP25fk0310531, JP26ck0106121 Japan Society for the Promotion of Science, https://ror.org/00hhkn466, JPJS00420240025, JP23K27397, JP26K02239